Array BioPharma Recruits Pierre Fabre As European Partner
This article was originally published in Scrip
The ability of Pierre Fabre to compete in the near term against oncology heavyweights like Novartis and Roche was key to selecting the French company to commercialize and further develop Array BioPharma's MEK inhibitor binimetinib and BRAF inhibitor encorafenib in Europe and emerging markets.
You may also be interested in...
Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.